JPMorgan Chase & Co. Acquires 22,249 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

JPMorgan Chase & Co. grew its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 16.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 160,722 shares of the biopharmaceutical company’s stock after purchasing an additional 22,249 shares during the quarter. JPMorgan Chase & Co. owned about 0.28% of Vanda Pharmaceuticals worth $754,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets lifted its stake in Vanda Pharmaceuticals by 1,184.6% in the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 57,393 shares during the period. FMR LLC increased its stake in shares of Vanda Pharmaceuticals by 25.9% in the 3rd quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after acquiring an additional 30,802 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter valued at approximately $864,000. Dimensional Fund Advisors LP boosted its stake in Vanda Pharmaceuticals by 17.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock worth $11,379,000 after acquiring an additional 292,172 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Vanda Pharmaceuticals during the third quarter valued at approximately $143,000. 88.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on VNDA shares. StockNews.com initiated coverage on Vanda Pharmaceuticals in a report on Monday, January 20th. They set a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, January 21st.

Vanda Pharmaceuticals Trading Down 0.5 %

VNDA opened at $4.40 on Monday. The stock has a market capitalization of $256.56 million, a P/E ratio of -15.71 and a beta of 0.77. Vanda Pharmaceuticals Inc. has a 12 month low of $3.46 and a 12 month high of $6.75. The firm’s fifty day simple moving average is $4.74 and its 200 day simple moving average is $5.00.

Insider Activity

In other news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the sale, the director now directly owns 44,857 shares in the company, valued at $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 8.90% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.